Overall, these observations suggest that inhibition of p27 specific phosphorylations, cooperating with CDK4 inhibitors [46], could be a strategy to target CDK4-dependent tumors such as estrogen receptor–positive breast cancers. The gene discussed is CDK4; the disease is breast carcinoma.